Information Provided By: 
Fly News Breaks for November 7, 2017
XLRN
Nov 7, 2017 | 13:53 EDT
H.C. Wainwright analyst Edward White raised his price target for Acceleron Pharma to $62 following the company's Q3 results and pipeline update citing an increase in cash levels. Acceleron indicated that it will have enough cash after its September offering to fund operations into 2021, White points out. He keeps an Outperform rating on the shares.
News For XLRN From the Last 2 Days
There are no results for your query XLRN
